Advertisement

Locoregional Recurrence of Breast Cancer

  • Jessica C. Gooch
  • Freya SchnabelEmail author
Chapter

Abstract

Patients with breast cancer are at risk of recurrence over many years after their initial breast cancer. Cancer may reoccur locally in the breast or chest wall or regionally in the lymph nodes. Full-body imaging and biopsy of suspected recurrences should be undertaken prior to multimodal treatment. This includes surgical resection to the extent possible, radiation and systemic chemotherapy, and hormonal treatment. The type of previous local and systemic therapy used for the index cancer will guide what modes of treatment are available for management of the recurrence.

Keywords

Recurrence Completion mastectomy Radiation Systemic therapy 

References

  1. 1.
    Lin NU, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013;22(3):203–10.CrossRefGoogle Scholar
  2. 2.
    Grotz TE, Boughey JC. Recurrent breast cancer. In: Wilke LG, Chagpar AB, editors. American Society of Breast Surgeons breast surgery manual: American Society of Breast Surgeons; 2012. www.breastsurgeons.org.
  3. 3.
    Shikama N, Sekiguchi K, Nakamura N. Management of locoregional recurrence of breast cancer. Breast Cancer. 2011;18(4):252–8.CrossRefGoogle Scholar
  4. 4.
    Navarro-Rodriguez E, et al. Factors associated with disease recurrence in breast cancer patients with negative sentinel lymph node biopsy. Clin Breast Cancer. 2016;16(6):e181–6.CrossRefGoogle Scholar
  5. 5.
    de Boniface J, et al. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study. Br J Surg. 2017;104(3):238–47.CrossRefGoogle Scholar
  6. 6.
    Krag DN, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.CrossRefGoogle Scholar
  7. 7.
    Bosma SC, et al. Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period. Breast Cancer Res Treat. 2016;156(2):391–400.CrossRefGoogle Scholar
  8. 8.
    Lowery AJ, et al. Locoregional recurrence after breast cancer surger: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133:831–41.CrossRefGoogle Scholar
  9. 9.
    Hattangadi-Gluth JA, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82(3):1185–91.CrossRefGoogle Scholar
  10. 10.
    Gillon P, et al. Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994/BIG 1-00 study. Eur J Cancer. 2017;79:226–34.CrossRefGoogle Scholar
  11. 11.
    Network, N.C.C. NCCN-evidence blocks–recurrent or stage IV disease. In: NCCN guidelines version 2.2016–invasive breast cancer. Fort Washington. www.nccn.org: National Comprehensive Cancer Network; 2016. p. 17–23.Google Scholar
  12. 12.
    Aebi S, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;15(2):156–63.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of SurgeryNYU Langone Health, NYU Perlmutter Cancer CenterNew YorkUSA

Personalised recommendations